Program
etrasimod
Also written as “Etrasimod”, “APD334” and “Etrasimod Immediate Release (IR)”.
Its studies are mostly in Colitis, Ulcerative · Dermatitis, Atopic · Crohn Disease · Alopecia Areata · Eosinophilic Esophagitis, led by 2 companies.
Drug pageEtrasimod: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 203 open or running | phase 3since May 8, 2019 | May 13, 2015 | Jun 16, 2029phase 2 · NCT05287126 |
| Everstar Therapeuticsits history only | 11 open or running | phase 3since Nov 22, 2019 | Nov 22, 2019 | none ahead |
Also a collaborator on its studies: Arena is a wholly owned subsidiary of Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 7 earlier studies, May 13, 2015 to May 8, 2019.
- Dec 9, 2016Named etrasimodINNProposed as its International Nonproprietary Name in WHO's List 116 · before, APD334
- Jun 21, 2019Phase 3 study in Colitis, UlcerativePfizer · NCT03996369 · 354 enrolled · United States, Argentina, Australia and more
- Nov 12, 2019Phase 2 study in Dermatitis, AtopicPfizer · NCT04162769 · 140 enrolled · United States, Australia, Canada
- Nov 20, 2019Phase 3 study in Crohn DiseasePfizer · NCT04173273 · 379 enrolled · United States, Argentina, Australia and more
- Nov 22, 2019Everstar Therapeutics’ first study: phase 3 study in Moderately to Severely Active Ulcerative ColitisNew to Everstar TherapeuticsEverstar Therapeutics · NCT04176588 · 341 enrolled · China
- Sep 15, 2020Phase 2 study in Alopecia AreataPfizer · NCT04556734 · 80 enrolled · United States, Canada
- Oct 23, 2020Phase 2 study in Colitis, UlcerativePfizer · NCT04607837 · 234 enrolled · United States, Australia, Belarus and more
- Dec 19, 2020Phase 2 study in Eosinophilic EsophagitisPfizer · NCT04682639 · 108 enrolled · United States, Australia, Belgium and more
- Jan 11, 2021Phase 3 study in Colitis, UlcerativePfizer · NCT04706793 · 42 enrolled · Japan
- Sep 20, 2021Phase 2 study in Colitis, UlcerativePfizer · NCT05061446 · 54 enrolled · Japan
- Mar 10, 2022Phase 2 study in Colitis, UlcerativePfizer · NCT05287126 · 36 planned · United States, Japan, Poland and more
- Dec 22, 2022Phase 3 study in Dermatitis, AtopicPfizer · NCT05732454 · 58 enrolled · United States, Canada, Czechia and more
- Nov 15, 2023Phase 1 study in Healthy ParticipantsPfizer · NCT06140290 · 8 enrolled · Belgium
- Aug 5, 2025Phase 1 study in Healthy ParticipantPfizer · NCT07153159 · 8 enrolled · Belgium
- Mar 10, 2026Phase 2 study in Colitis, UlcerativePfizer · NCT07470879 · 24 planned · United States, Australia, Canada and more
Ahead
- Jun 16, 2029Primary completion: phase 2 study in Colitis, UlcerativePfizer · NCT05287126
- Jun 19, 2029Primary completion: phase 3 study in Colitis, UlcerativePfizer · NCT03950232
- Sep 8, 2030Primary completion: phase 2 study in Colitis, UlcerativePfizer · NCT07470879
TargetBeta
“Sphingosine 1-phosphate receptor Edg-1 agonist; Sphingosine 1-phosphate receptor Edg-6 modulator; Sphingosine 1-phosphate receptor Edg-1 modulator; Sphingosine 1-phosphate receptor Edg-8 modulator”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| fingolimodrule | Novartis | phase 4 | 55 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07470879Colitis, Ulcerative · United States, Australia, Canada and more | 2 | Recruiting | Pfizer | Sep 8, 2030 | 24 |
| NCT07153159Healthy Participant · Belgium | 1 | Completed | Pfizer | Sep 18, 2026 | 8 |
| NCT06140290Healthy Participants · Belgium | 1 | Completed | Pfizer | Mar 1, 2024 | 8 |
| NCT05732454Dermatitis, Atopic · United States, Canada, Czechia and more | 3 | Terminated | Pfizer | Apr 29, 2024 | 58 |
| NCT05287126Colitis, Ulcerative · United States, Japan, Poland and more | 2 | Recruiting | Pfizer | Jun 16, 2029 | 36 |
| NCT05061446Colitis, Ulcerative · Japan | 2 | Completed | Pfizer | Oct 6, 2023 | 54 |
| NCT04706793Colitis, Ulcerative · Japan | 3 | Completed | Pfizer | Aug 3, 2022 | 42 |
| NCT04682639Eosinophilic Esophagitis · United States, Australia, Belgium and more | 2 | Completed | Pfizer | Sep 30, 2022 | 108 |
| NCT04607837Colitis, Ulcerative · United States, Australia, Belarus and more | 2 | Completed | Pfizer | Jun 19, 2024 | 234 |
| NCT04556734Alopecia Areata · United States, Canada | 2 | Completed | Pfizer | Jun 7, 2023 | 80 |
| NCT04176588Moderately to Severely Active Ulcerative Colitis · China | 3 | Active, not recruiting | Everstar Therapeutics | Jul 2024 | 341 |
| NCT04173273Crohn Disease · United States, Argentina, Australia and more | 3 | Terminated | Pfizer | Apr 23, 2025 | 379 |
| NCT04162769Dermatitis, Atopic · United States, Australia, Canada | 2 | Completed | Pfizer | Sep 9, 2020 | 140 |
| NCT03996369Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Dec 7, 2021 | 354 |
| NCT03950232Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Jun 19, 2029 | 896 |
| NCT03945188Colitis, Ulcerative · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Feb 8, 2022 | 433 |
| NCT03155932Liver Cirrhosis, Biliary · United States, Australia, New Zealand | 2 | Terminated | Pfizer | Jan 31, 2019 | 2 |
| NCT03139032Inflammatory Bowel Diseases · Belgium, Germany, Serbia | 2 | Terminated | Pfizer | Dec 6, 2017 | 1 |
| NCT03072953Pyoderma Gangrenosum · Australia, New Zealand | 2 | Terminated | Pfizer | May 22, 2018 | 2 |
| NCT02536404Colitis, Ulcerative · United States, Australia, Austria and more | 2 | Completed | Pfizer | Nov 1, 2018 | 118 |
| NCT02447302Colitis, Ulcerative · United States, Australia, Austria and more | 2 | Completed | Pfizer | Feb 14, 2018 | 156 |
How it is read
Names in the registry
- “Etrasimod”, 19 entries
- “APD334”, 3 entries
- “etrasimod”, 1 entry
- “Etrasimod Immediate Release (IR)”, 1 entry
- “Etrasimod 1 mg”, 1 entry
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 11 studies
- Dermatitis, Atopic, 2 studies
- Crohn Disease, 1 study
- Alopecia Areata, 1 study
- Eosinophilic Esophagitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.